Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China
Tóm tắt
Molecular epidemiological studies have shown that gene polymorphisms of vitamin D receptor (VDR) are associated with prostate cancer risks. However, previous results from many molecular studies remain inconsistent. Blood samples were collected from 122 prostate cancer patients and 130 age-matched control subjects in the Han population of Southern China. The differences of VDR gene polymorphism between cancer cases and controls were determined by PCR-RFLP, examiming FokI (exon 2), BsmI, Tru9I, ApaI (intron 9), and TaqI (exon 9). Associations between the VDR gene polymorphism and prostate cancer risk were calculated in an unconditional logistic regression model. Linkage disequilibrium and haplotypes were analyzed with the SHEsis software. Of five polymorphisms, BsmI was shown to associate with prostate cancer, while FokI, Tru9I, ApaI, and TaqI did not show any significant association. After adjustment for age, the BsmI 'B' allele was associated with an almost 1/3-fold risk (OR = 0.35, 95%CI: 0.15-0.80) of the occurrence of prostate cancer, a 1/5-fold risk (OR = 0.20, 95%CI: 0.06-0.68) of poorly differentiated prostate cancer, and a 1/10-fold risk (OR = 0.10, 95%CI: 0.01-0.78) of aggressive prostate cancer compared with the 'b' allele, especially among older men (>71 years). In addition, haplotype analysis revealed that the 'F-b-U-A-T' was more frequent found in cases than in controls (3.4% vs 0.0%, P = 0.0035), while the frequency of haplotype 'F-B-U-a-T' was 0.8% in cases, significantly lower than in controls (3.9%, P = 0.019). Our experiments provide evidences that genetic polymorphisms in the VDR gene may be potential risk factors for prostate cancer in the Han population of southern China and the susceptibility to prostate cancer is associated with ethnicity and geographic location.
Từ khóa
Tài liệu tham khảo
American Cancer Society: Cancer Facts and Figures. 2003, [http://www.cancer.org/docroot/home/index.asp]
Quinn M, Babb P: Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int. 2002, 90: 162-173. 10.1046/j.1464-410X.2002.2822.x.
Ostrander EA, Stanford JL: Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet. 2000, 67: 1367-1375. 10.1086/316916.
The incidence of cancer in Shanghai city in 1983-2005. Tumor. 2008, 28: 571-
Gu FL: Changing constituents of genitourinary cancer in recent 50 years in Beijing. Chin Med J (Eng l). 2003, 116: 1391-1393.
Zhang HF, Wang HL, Xu N, Li SW, Ji GY, Li XM, Pang YZ, Zhang L, Zhao XJ, Gao HW: Mass screening of 12027 elderly men for prostate carcinoma by measuring serum prostate specific antigen. Chin Med J (Eng l). 2004, 117: 67-70.
Schwartz GG, Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res. 1990, 10: 1307-1311.
Hanchette CL, Schwartz GG: Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer (Phila.). 1992, 70: 2861-2869. 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G.
Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P: The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1a,25 dihydroxyvitamin D3. Cancer Res. 1992, 52: 515-520.
Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D: Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994, 54: 805-810.
Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP: 1a,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 1997, 6: 727-732.
Guzey M, Kitada S, Reed JC: Apoptosis induction by 1alpha, 25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther. 2002, 1: 667-677.
Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA: Prediction of bone density from vitamin D receptor alleles. Nature. 1994, 367: 284-287. 10.1038/367284a0.
Saijo T, Ito M, Takeda E, Huq AH, Naito E, Yokota I, Sone T, Pike JW, Kuroda Y: A unique mutation in the vitamin D receptor gene in three Japanese patients with vitamin D-dependent rickets type II: utility of single-strand conformation polymorphism analysis for heterozygous carrier detection. Am J Hum Genet. 1991, 49: 668-673.
Miyamoto K, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, Inoue Y, Morita K, Takeda E, Pike JW: Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol. 1997, 11: 1165-1179. 10.1210/me.11.8.1165.
Arai H, Miyamoto K, Taketani Y, Yamamoto H, Iemori Y, Morita K, Tonai T, Nishisho T, Mori S, Takeda E: A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res. 1997, 12: 915-921. 10.1359/jbmr.1997.12.6.915.
Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA: Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res. 1996, 56: 4108-4110.
Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst (Bethesda). 1997, 89: 166-170. 10.1093/jnci/89.2.166.
Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM: Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomarkers Prev. 2003, 12: 23-27.
Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, Akao T, Tsuchiya N, Shimoda N, Wada Y, Koizumi A, Chihara J, Ogawa O, Kato T: Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res. 2000, 60: 305-308.
Cheteri MB, Stanford JL, Friedrichsen DM, Peters MA, Iwasaki L, Langlois MC, Feng Z, Ostrander EA: Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate. 2004, 59: 409-418. 10.1002/pros.20001.
Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Lopes C: The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. J Hum Genet. 2002, 47: 413-418. 10.1007/s100380200060.
John EM, Schwartz GG, Koo J, Den Berg, Ingles SA: Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Risk of Advanced Prostate Cancer. Cancer Res. 2005, 65: 5470-5479. 10.1158/0008-5472.CAN-04-3134.
Patiyan A, Eberhard V, Peter S: Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk. Eur J Cancer. 2006, 42: 2833-2837. 10.1016/j.ejca.2006.06.030.
Oakley-Girvan I, Feldman D, Eccleshall TR, Gallagher RP, Wu AH, Kolonel LN, Halpern J, Balise RP, West DW, Paffenbarger Jr, Whittemore AS: Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol Biomarkers Prev. 2004, 13: 1325-1330.
Correa-Cerro L, Berthon P, Haussler J, Bochum S, Drelon E, Mangin P, Fournier G, Paiss T, Cussenot O, Vogel W: Vitamin D receptor polymorphisms as markers in prostate cancer. Hum Genet. 1999, 105: 281-287. 10.1007/s004390051102.
Cicek MS, Liu X, Schumacher FR, Casey G, Witte JS: Vitamin D Receptor Genotypes/Haplotypes and Prostate Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2006, 15: 2549-2552. 10.1158/1055-9965.EPI-06-0409.
Ingles SA, Coetzee GA, Ross RK, Henderson BE, Kolonel LN, Crocitto L, Wang W, Haile RW: Association of prostate cancer with vitamin D receptor haplotype in African-Americans. Cancer Res. 1998, 58: 1620-1623.
Hayes VM, Severi G, Padilla EJ, Eggleton SA, Southey MC, Sutherland RL, Hopper JL, Giles GG: Genetic variants in the vitamin D receptor gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2005, 14: 997-999. 10.1158/1055-9965.EPI-04-0660.
Berndt SI, Dodson JL, Huang WY, Nicodemus KK: A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol. 2006, 175: 1613-1623. 10.1016/S0022-5347(05)00958-4.
Yang Y, Wang S, Ye Z, Yang W: Association of single nucleotide polymorphism of vitamin D receptor gene start codon and the susceptibility to prostate cancer in the Han nationality in Hubei area. Zhonghua Nan Ke Xue. 2004, 10: 411-414.
Liu JH, Li HW, Wang JQ, Li M, Xin DQ, Na X, Zhang M, Ye SY, Na YQ: Vitamin D receptor gene BsmI polymorphism and the susceptibility to prostate cancer in northern Chinese Han population. Zhonghua Nan Ke Xue. 2003, 9: 413-416.
Chokkalingam AP, McGlynn KA, Gao YT, Pollak M, Deng J, Sesterhenn IA, Mostofi FK, Fraumeni JF, Hsing AW: Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. Cancer Res. 2001, 61: 4333-4336.
Gleason DF, Mellinger GT: Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol. 1974, 111: 58-64.
Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005, 15: 97-98. 10.1038/sj.cr.7290286.
Huang SP, Chou YH, Wayne Chang, Wu MT, Chen YY, Yu CC, Wu TT, Lee YH, Huang JK, Wu WJ, Huang CH: Association between vitamin D receptor gene polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett. 2004, 207: 69-77. 10.1016/j.canlet.2003.12.006.
Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ: Vitamin D receptor polymorphisms, circulating vitamin D metabolites and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomark Prev. 1998, 7: 385-390.
Morrison NA, Yeoman R, Kelly PJ, Eisman J: Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphisms and circulating osteocalcin. Proc Nail Acad Sci USA. 1992, 89: 6665-6669. 10.1073/pnas.89.15.6665.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/10/125/prepub